IOVA
Iovance Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.84B
P/E Ratio
—
EPS
$-0.92
Beta
0.69
52W High
$5.63
52W Low
$1.66
50-Day MA
$3.63
200-Day MA
$2.82
Dividend Yield
—
Profit Margin
-123.90%
Forward P/E
—
PEG Ratio
0.00
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Fundamentals
| Revenue (TTM) | $285.61M |
| Gross Profit (TTM) | $112.64M |
| EBITDA | $-321.62M |
| Operating Margin | -113.50% |
| Return on Equity | -47.50% |
| Return on Assets | -23.60% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $1.65 |
| Price-to-Book | 2.54 |
| Price-to-Sales (TTM) | 6.43 |
| EV/Revenue | 5.5 |
| EV/EBITDA | -8.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 44.80% |
| Shares Outstanding | $446.50M |
| Float | $387.98M |
| % Insiders | 0.33% |
| % Institutions | 67.37% |
Historical Volatility
HV 10-Day
69.58%
HV 20-Day
86.24%
HV 30-Day
78.22%
HV 60-Day
91.02%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($8.80 target)
2
Strong Buy6
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026